Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M3T01 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT06719362Phase 1Recruiting
- Start
- Jun 2025
- Primary completion
- Feb 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of M3T01 in solid tumor, glioblastoma (GBM), esophageal adenocarcinoma (EAC) and 3 more (11 arms). Primary endpoints: Treatment-emergent adverse events at 4 years, Dose-limiting toxicities at 21 days and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
M3T01
03
Conditions
solid tumorglioblastoma (GBM)esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on NCT06719362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719362.